SML2588
JNJ0966
≥98% (HPLC)
别名:
N-[2-[(2-Methoxyphenyl)amino]-4′-methyl[4,5′-bithiazol]-2′-yl]acetamide
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C16H16N4O2S2
化学文摘社编号:
分子量:
360.45
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
产品名称
JNJ0966, ≥98% (HPLC)
SMILES string
[s]1c(nc(c1c2nc([s]c2)Nc3c(cccc3)OC)C)NC(=O)C
InChI
1S/C16H16N4O2S2/c1-9-14(24-16(17-9)18-10(2)21)12-8-23-15(20-12)19-11-6-4-5-7-13(11)22-3/h4-8H,1-3H3,(H,19,20)(H,17,18,21)
InChI key
ZADCDCMLLGDCRM-UHFFFAOYSA-N
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
2-8°C
Biochem/physiol Actions
JNJ0966 is a potent and highly selective inhibitor of matrix metalloproteinase-9 (MMP-9) zymogen activation. It appears that JNJ0966 binds to a structural pocket in proximity to the MMP-9 zymogen cleavage site near Arg-106. JNJ0966 reduces disease severity in in a mouse experimental autoimmune encephalomyelitis (EAE) model. JNJ0966 does not inhibit activation of MMP-2 zymogen, and has no effect on MMP-1, MMP-2, MMP-3, MMP-9 or MMP-14 catalytic activity.
potent and highly selective inhibitor of matrix metalloproteinase-9 (MMP-9) zymogen activation
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
Robert H Scannevin et al.
The Journal of biological chemistry, 292(43), 17963-17974 (2017-09-02)
Aberrant activation of matrix metalloproteinases (MMPs) is a common feature of pathological cascades observed in diverse disorders, such as cancer, fibrosis, immune dysregulation, and neurodegenerative diseases. MMP-9, in particular, is highly dynamically regulated in several pathological processes. Development of MMP
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持